Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Current Deferred Revenue (2020 - 2025)

PROCEPT BioRobotics (PRCT) has disclosed Current Deferred Revenue for 6 consecutive years, with $13.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue rose 36.41% to $13.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.0 million, a 36.41% increase, with the full-year FY2025 number at $13.0 million, up 36.41% from a year prior.
  • Current Deferred Revenue was $13.0 million for Q4 2025 at PROCEPT BioRobotics, up from $10.7 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $13.0 million in Q4 2025 to a low of $848000.0 in Q3 2021.
  • A 5-year average of $5.7 million and a median of $5.3 million in 2023 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: soared 339.91% in 2021, then surged 33.5% in 2025.
  • PROCEPT BioRobotics' Current Deferred Revenue stood at $1.0 million in 2021, then skyrocketed by 178.54% to $2.9 million in 2022, then soared by 98.11% to $5.7 million in 2023, then soared by 69.11% to $9.6 million in 2024, then surged by 36.41% to $13.0 million in 2025.
  • Per Business Quant, the three most recent readings for PRCT's Current Deferred Revenue are $13.0 million (Q4 2025), $10.7 million (Q3 2025), and $9.9 million (Q2 2025).